Nizatidine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Nizatidine. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Headache | 16.6% |
| Abdominal pain | 12.5% |
| Rhinitis | 9.8% |
| Nausea | 7.4% |
| Diarrhea | 7.2% |
| Vomiting | 5.6% |
| Flatulence | 5.4% |
| Dizziness | 4.6% |
| Dyspepsia | 4.4% |
| Pain | 4.2% |
| Constipation | 3.8% |
| Insomnia | 3.4% |
| Pharyngitis | 3.3% |
| Asthenia | 3.1% |
| Back pain | 2.6% |
| Sinusitis | 2.4% |
| Chest pain | 2.3% |
| Fever | 2.3% |
| Rash | 2.1% |
| Cough, increased | 2% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.